Trial · NCT06422975
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Characterise the clinical practice of vasopressin use in the context of shock in a multicentre observational study. | 90 days | Describing the time sequence of vasopressin and/or noradrenaline use (what is initiated first) during shock |
| Secondary | Assess what prompted the decision to initiate AVP | Up to 7 days | Assess what prompted the decision to initiate AVP: type of shock (vasoplegic, hypovolemic,...), perfusion parameters (as lactate) or noradrenaline dose (microgram/kg/minute) |
| Secondary | Define the impact of starting AVP on noradrenaline dose | Up to 7 days | Define the impact of starting AVP on noradrenaline dose (microgram/kg/minute) |
| Secondary | Define the impact of starting AVP on lactate level | Up to 7 days | Define the impact of starting AVP on lactate level (mmol/L) |
| Secondary | Observe when AVP is discontinued and how | Up to 7 days | Describe number of participants what AVP is discontinued first and how (abruptly or progressively) |
| Secondary | Estimate the range of doses of AVP used | Up to 7 days | Estimate the range of doses of AVP used and the maximum dose used in routine clinical practice. |
| Secondary | Incidence of side effects | Up to 7 days | Describe the incidence of side effects, whether it is related to AVP dose and patients' comorbidities. |
| Secondary | 28-day all-cause mortality | 28 days | Death on or before study day 28 |
| Secondary | 90-day all-cause mortality | 90 days | Death on or before study day 90 |
| Secondary | Incidence of new renal replacement therapy | From onset of shock until hospital discharge, an average of 2 weeks | New receipt of renal replacement therapy after onset of shock |
| Secondary | Vasopressor-free days to day 28 | 28 days | Number of days between day 28 and the end of the last period of vasopressor therapy prior to day 28 |
| Secondary | Intensive care unit-free days to day 28 | 28 days | Number of days between day 28 and the end of the last period of intensive care unit admission prior to day 28. |
| Secondary | Hospital-free days to day 28 | 28 days | Number of days between day 28 and the end of the last period of hospital admission prior to day 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06422975/registered